
|Articles|October 1, 2012
Unapproved neurotoxins abound, dermatologist warns
The approval of the newest botulinum toxin product available in the United States underscores the value of the Food and Drug Administration drug approval process and the importance of using branded products, says Mich?l H. Gold, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Dermatology Conferences and Meetings Calendar: December 2025
4
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
5


















